# SuppreMol

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/suppremol

- Industry: Pharmaceuticals
- Headquarters: Munich, Germany
- Website: www.suppremol.com
- Total disclosed funding: $63M
- Latest round: Series D (May 22, 2013)
- Investors on record: 8

## About

SuppreMol, is based in Munich, Germany and a privately held
biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases.

## Funding rounds

- Series D, May 22, 2013, $12M — BioMed Partners, MIG Capital, FCP Biotech Holding GmbH, Max Planck Society, Santo Holding
- Series C, Dec 1, 2010, $21M — KfW Banking Group, BioMed Partners, MIG Capital, Bayern Kapital, FCP Biotech Holding GmbH, Santo Holding
- Series B, Jul 1, 2008, $25M — KfW Banking Group, BioMed Partners, MIG Capital, Bayern Kapital, Z-Cube, Max Planck Society, Santo Holding
- Series A, May 24, 2006, $5.2M — KfW Banking Group, Bayern Kapital, Z-Cube

## Investors

- KfW Banking Group — Series A, Series B, Series C
- Bayern Kapital (https://capitalatlas.ai/funds/bayern-kapital) — Series A, Series B, Series C
- Z-Cube — Series A, Series B
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series B, Series C, Series D
- MIG Capital (https://capitalatlas.ai/funds/mig-capital) — Series B, Series C, Series D
- Max Planck Society — Series B, Series D
- Santo Holding — Series B, Series C, Series D
- FCP Biotech Holding GmbH — Series C, Series D